Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL ( l session results of an ongoing trial ...)

HOME >> MEDICINE >> TECHNOLOGY

Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

l session, results of an ongoing trial of ISIS 301012 added to maximal lipid lowering therapies in homozygous familial hypercholesterolemia (FH) patients were reported. Results of polygenic hypercholesterolemic patients treated with up to 400 mg/week of ISIS 301012 for up to three months as a single agent are the subject of a v-cast poster presentation. Results for the extended three-month treatment cohorts at 200 and 300 mg/week doses in the statin coadministration study are expected later in the year. Also later in the year, results from an ongoing double-blind, placebo-controlled, dose-escalation study in patients with heterozygous FH will be reported.

ISIS 301012 has been granted orphan drug status for the treatment of homozygous FH and Isis plans to begin registration-directed studies for FH in 2007.

About ISIS 301012 and Cholesterol

ISIS 301012 is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol and a target that has proved to be undruggable using traditional, small-molecule approaches. Cholesterol can be carried in the bloodstream in a variety of forms, with high-density lipoprotein, or HDL-C, being the good form, and low-density lipoproteins, or LDL-C, and very low-density lipoproteins, or VLDL-C, being bad forms directly involved in heart disease. Collectively, LDL-C, VLDL-C, and other bad forms of cholesterol are referred to as "non-HDL-C." The lowering of non-HDL-C is a key component in the prevention and management of cardiovascular disease. Isis plans to develop ISIS 301012 as the drug of choice for patients who are unable to achieve target cholesterol levels with statins alone or who are intolerant of statins.

Adult Treatment Panel III Recommendations

The National Cholesterol Education Program's Adult Treatment Panel III guidelines for target LDL-C levels High-Risk patients is less than 100 mg/dL, with an optional target
'"/>

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:

(Date:5/23/2013)... SAN DIEGO , May 23, 2013 Neurocrine ... Kevin Gorman , President and Chief Executive ... Bank 38 th Annual dbAccess Health Care Conference in ... Thursday, May 30 at 11:20 a.m. Eastern Time / 8:20 ... be accessed on the Company,s website at http://www.neurocrine.com . ...

(Date:5/23/2013)... MGC Diagnostics Corporation (NASDAQ: MGCD ) ... scheduled a conference call to discuss its financial results ... April 30, 2013. The call will be at 4:30 ... will report financial results for the second quarter of ... May 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO ...

(Date:5/23/2013)... 2013 The need to add tissue preserving ... highlighted prominently at the 108 th Annual ... San Diego. According to SonaCare Medical, a leader ... technology, the need for image-guided technologies to better ... consider minimally invasive ablative treatments, was addressed in ...

Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2 Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2 Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3 Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4 Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5 Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6

[0] Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference [0] MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 [0] Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting

... CSL Behring has been informed by the U.S. Food ... first FDA-approved treatment of acute bleeding episodes in patients ... seven years of orphan-drug exclusivity. RiaSTAP was approved ... the treatment of acute bleeding episodes in patients with ...

... Medicated Arthri-Zen Relief Cream(R) Clinically Shown to Work for up ... Americans suffer from the aches and pains that come with ... effective ways to get fast relief from arthritis pain is ... the relief tends to be short-lived. Many people find that ...

Cached Medicine Technology:CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 2 CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 3 CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 4 Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain 2 Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain 3

CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain

(Date:5/25/2013)... MA (PRWEB) May 25, 2013 Imagine running ... -- the energy loss, hot air and wasted energy! If ... house fan, a fireplace or clothes dryer, that may be ... Drafts from these often overlooked holes waste energy in the ... of heating and cooling loss in the home. , Drafts ...

(Date:5/25/2013)... 25, 2013 Dr. Leslie Gerstman ... FDA-approved to lift skin on the neck, on the brow ... practice, Medical Aesthetics. , Ultherapy is a non-surgical procedure for ... healing process to lift the skin over time. The use ... to see and then treat the deepest support layers of ...

(Date:5/25/2013)... Communities of Distinction TV announces May air ... media market in the United States with almost three million ... Texas and a major convention city. Ft. Worth is known ... is home to many major museums. Both cities offer a ... arts. Residents and locals will be able to watch the ...

(Date:5/25/2013)... and parasites that affect both dogs and humans, such ... can result in liver or kidney failure -- may ... These germs could be found in the ... Nelson, a clinical associate professor at Kansas State University,s ... be fatal, even with treatment," she said in a ...

(Date:5/25/2013)... United States (PRWEB) May 25, 2013 ... and largest underground shelter company in the US ... composite underground structures for over 35 years. M.E. ... PROTECTION, U.S. Handbook of NBC Weapon Fundamentals and ... the United States’ bible on shelter engineering. McCarthy ...

Breaking Medicine News(10 mins):Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 2 Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 3 Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 4 Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2 Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2 Health News:Hidden Dangers Dog Dog Parks 2 Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2 Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3

[0] How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation [0] Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ [0] Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas [0] Hidden Dangers Dog Dog Parks [0] Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster

... to be Featured on Yahoo! Answers -, The Partnership Joins Dr. ... ... Abuse Treatment, NEW YORK, Jan. 9 The Partnership for a ... "Celebrity Rehab With Dr. Drew," is helping support the,Partnership,s new cause marketing ...

... fuel debate about screening for cardiovascular problems , , WEDNESDAY, ... identified an abnormal heartbeat pattern in young athletes that ... later in life. , The report comes amid intense ... potential cardiac problems, said Dr. Mark S. Link, director ...

... only been a few weeks since you made that New Years ... days maybe even weeks. , You know all the ... which would obviously be nice, exercise has been linked to reduced ... of sitting on the couch and watching TV instead of going ...

... Texas Mutual Insurance Company, an,aggressive tort reform advocate in ... litigation in which the insurance company tried,to overturn an ... a workplace injury,a Dallas state district judge ruled today., ... medical record,Texas Mutual had no evidence to continue to ...

... N.J., Jan. 9 Managed Health Care,Associates, Inc. ... the addition of two outside members, Mr. Barry ... Board of Directors. Mr. Freedman and Mr.,Wheelan join ... Diamond Castle Holdings, LLC., Barry Freedman is ...

... AlphaRx (OTC BB:ALRX -,News) stated on Tuesday that CEO ... in the open market, bringing the total number of,shares ... his,continued confidence in the Company,s future., Mr. Michael ... for,an average price of $0.24 each, increasing his holdings ...

Dr. Drew Joins the Partnership for a Drug-Free America in Supporting TimeToTalk(TM)Test Finds Rare Heart Defect in Some Young Athletes Exercising judgment: The psychology of fitness Judge Rules Texas Mutual Insurance Co. Committed Litigation Fraud With Falsified Document, According to Doyle Raizner LLP MHA Announces: Managed Health Care Associates, Inc. (MHA) Expands Board of Directors AlphaRx CEO Accumulates More Company Shares

For the qualitative detection of single and multiple drugs and drug metabolites in human urine...

Medicine Products:

SureStep THC COC MAMPII SureStep Ecstasy (MDMA)SureStep Cocaine (COC)SureStep Amphetamines (AMP)